Ifinatamab deruxtecan

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameIfinatamab deruxtecan
Drug Alias NameDS-7300DS-7300aMABX-9001aI-DXdMK-2400
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload
Mechanisms of ActionCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[41] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdHarpoon Therapeutics IncMerck Sharp & Dohme Corp +[8] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisProstatic Neoplasms, Castration-Resistant +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG